Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
HC Wainwright & Co. : The Phathom Pharmaceuticals (PHAT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. : The Phathom Pharmaceuticals (PHAT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.
Phathom Pharmaceuticals | 10-Q: Quarterly report
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Phathom Pharmaceuticals Says It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
Phathom Pharmaceuticals Says It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
Phathom Pharmaceuticals Q1 2024 GAAP EPS $(1.42) Misses $(1.28) Estimate, Sales $1.912M Miss $2.047M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 59.55 percent decrease over loss
Phathom Pharmaceuticals 1Q Loss/Shr $1.42 >PHAT
Phathom Pharmaceuticals 1Q Loss/Shr $1.42 >PHAT
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Promising Pipeline Developments
Phathom a Buy at Stifel on New Heartburn Therapy
Buy Rating Affirmed for Phathom Pharmaceuticals on V Oquezna's Promising Market Trajectory
Phathom Pharmaceuticals (PHAT.US) was first covered by Stifel, giving it a buy rating, with a target price of $24.00.
Phathom Pharmaceuticals (PHAT.US) was first covered by Stifel, giving it a buy rating, with a target price of $24.00.
Stifel Initiates Coverage On Phathom Pharmaceuticals With Buy Rating, Announces Price Target of $24
Stifel analyst Annabel Samimy initiates coverage on Phathom Pharmaceuticals with a Buy rating and announces Price Target of $24.
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ETFLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical c
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals' V Oquezna
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m...
13D Filings -- Barron's
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
12 Most Shorted Stocks in 2024
No Data